Compare THS & SVRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | THS | SVRA |
|---|---|---|
| Founded | 2021 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Packaged Foods | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.2B |
| IPO Year | N/A | N/A |
| Metric | THS | SVRA |
|---|---|---|
| Price | $24.60 | $5.63 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 7 | 9 |
| Target Price | ★ $24.67 | $7.33 |
| AVG Volume (30 Days) | 658.3K | ★ 1.3M |
| Earning Date | 02-13-2026 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $3,336,000,000.00 | N/A |
| Revenue This Year | $1.43 | N/A |
| Revenue Next Year | $0.65 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $15.85 | $1.89 |
| 52 Week High | $40.77 | $7.01 |
| Indicator | THS | SVRA |
|---|---|---|
| Relative Strength Index (RSI) | 72.17 | 45.17 |
| Support Level | $24.43 | $5.33 |
| Resistance Level | $24.73 | $6.49 |
| Average True Range (ATR) | 0.19 | 0.28 |
| MACD | 0.00 | -0.06 |
| Stochastic Oscillator | 75.14 | 24.57 |
TreeHouse Foods is the largest pure-play private-label manufacturer in the US. Much larger in the past following the 2016 acquisition of Ralcorp, Conagra's former private-label business, the company has since divested several businesses to focus on high-growth categories. At present, the company produces and sells snacks (crackers, pretzels, cookies, and so on), beverages (such as nondairy creamer, coffee, tea, and broth), and a select number of grocery products (pickles, refrigerated dough, hot cereal, cheese, and pudding). Its most important sales channel is through retail grocery stores that sell its products under their own brands, with co-manufacturing and food away from home as much smaller channels of distribution for its fare.
Savara Inc is a biopharmaceutical company. It is focused on rare respiratory diseases. The company's program, molgramostim nebulizer solution (molgramostim), is an inhaled granulocyte-macrophage colony-stimulating factor in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP). It has one segment specialty pharmaceuticals within the respiratory system.